MedTrace Logo

Effect of Gelsectan® in the Treatment of Low Anterior Resection Syndrome

NCT06162143 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2024-01-10

No results posted yet for this study

Summary

Low Anterior Resection Syndrome (LARS) is an intestinal disorder affecting patients undergoing rectal resection for rectal cancer. A possible therapeutic option may be Gelsectan®, a class II device used in Irritable Bowel Syndrome (IBS). The aim of this study is to evaluate the efficacy of Gelsectan® in improving the symptoms of LARS.

Conditions

  • Low Anterior Resection Syndrome

Interventions

DEVICE

Gelsectan®

Gelsectan® is a CE-marked class II device containing xyloglucans, xylo-oligosaccharides, pea proteins, and tannins from grape seeds extract, already used in Irritable Bowel Syndrome (IBS).

Sponsors & Collaborators

  • Istituto Clinico Humanitas

    lead OTHER

Principal Investigators

  • Antonino Spinelli, MD,PhD · Humanitas Research Hospital IRCCS, Rozzano-Milan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2025-06-15
Completion
2025-11-15

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06162143 on ClinicalTrials.gov